WASHINGTON – President Donald Trump is “doing very well,” the president’s physician told reporters on Saturday hours after the president was taken to the hospital after experiencing fever, congestion and symptoms from coronavirus.
“This morning, the president is doing very well,” said Dr. Sean Conley, who said he was “extremely happy” with the president’s progress so far.
Doctors said the president had been fever free for over 24 hours and was not on oxygen Saturday but did not answer several questions about whether he had been at any point previously. Trump’s medical team denied a report Friday that the president was having trouble breathing.
“He’s not on oxygen right now,” Conley said, adding that Trump had an oxygen saturation level of 96%, within the normal range for a healthy person.
Doctors monitor oxygen in blood as an indicator of whether there’s low oxygen levels, one of the problems that occurs with COVID-19.
Conley said the president developed a fever Thursday and said that doctors were continuing to evaluate when he could return to the White House. Asked why, specifically, he had been transferred to Walter Reed, Conley indicated it was out of an abundance of caution.
“Because he’s the president of the United States,” Conley said.
Trump, 74, remained at Walter Reed Medical Center in Bethesda, Maryland, on Saturday after he and first lady Melania Trump announced early Friday they had tested positive for COVID-19. White House officials, who initially described the president’s case as mild, later said he was experiencing symptoms such as fatigue and fever.
Soon after Trump arrived at the hospital, the White House released a memo from Conley indicating the president was starting remdesivir therapy. Conley said at that time that Trump was “doing very well” and was “resting comfortably.”
Trump also received a single 8-gram dose of Regeneron’s polyclonal antibody cocktail as a precautionary measure, according to Conley. The antibody cocktail is being studied in four late-stage clinical trials and its safety and efficacy have not been fully evaluated by any regulatory authority, the company said on its page.
